AU Patent

AU2004270211A1 — Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Assigned to Celgene Corp · Expires 2005-03-17 · 21y expired

What this patent protects

Patent listed against Revlimid.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004270211A1
Jurisdiction
AU
Classification
—
Expires
2005-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.